BR9909878A - 10-paroxetine camphosulfonate for treatment of central nervous system disorders - Google Patents

10-paroxetine camphosulfonate for treatment of central nervous system disorders

Info

Publication number
BR9909878A
BR9909878A BR9909878-4A BR9909878A BR9909878A BR 9909878 A BR9909878 A BR 9909878A BR 9909878 A BR9909878 A BR 9909878A BR 9909878 A BR9909878 A BR 9909878A
Authority
BR
Brazil
Prior art keywords
paroxetine
treatment
nervous system
central nervous
camphosulfonate
Prior art date
Application number
BR9909878-4A
Other languages
Portuguese (pt)
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9909878A publication Critical patent/BR9909878A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Abstract

"10-CANFOSULFONATO DE PAROXETINA PARA TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL" Os 10-canfosulfonatos de paroxetina são úteis no tratamento de certos distúrbios do Sistema Nervoso Central."10-PAROXETINE CAMPHOSULPHONATE FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS" Paroxetine 10-camphosulfonates are useful in the treatment of certain disorders of the Central Nervous System.

BR9909878-4A 1998-04-25 1999-04-23 10-paroxetine camphosulfonate for treatment of central nervous system disorders BR9909878A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808894.1A GB9808894D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001246 WO1999055699A1 (en) 1998-04-25 1999-04-23 Paroxetine 10-camphorsulfonate for treatment of cns disorders

Publications (1)

Publication Number Publication Date
BR9909878A true BR9909878A (en) 2000-12-26

Family

ID=10831007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909878-4A BR9909878A (en) 1998-04-25 1999-04-23 10-paroxetine camphosulfonate for treatment of central nervous system disorders

Country Status (18)

Country Link
EP (1) EP1076659A1 (en)
JP (1) JP2002513020A (en)
KR (1) KR20010042929A (en)
CN (1) CN1306530A (en)
AP (1) AP2000001958A0 (en)
AU (1) AU3618699A (en)
BG (1) BG104973A (en)
BR (1) BR9909878A (en)
CA (1) CA2329913A1 (en)
EA (1) EA200001105A1 (en)
GB (1) GB9808894D0 (en)
HU (1) HUP0102298A2 (en)
IL (1) IL139018A0 (en)
NO (1) NO20005351D0 (en)
PL (1) PL343596A1 (en)
SK (1) SK15902000A3 (en)
TR (1) TR200003083T2 (en)
WO (1) WO1999055699A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Paroxetine cholate or cholic acid derivative salts
CN104402708A (en) * 2014-12-07 2015-03-11 河南领先科技药业有限公司 Production method for sodium camphorate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
HU221921B1 (en) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them

Also Published As

Publication number Publication date
EA200001105A1 (en) 2001-04-23
NO20005351L (en) 2000-10-24
AU3618699A (en) 1999-11-16
EP1076659A1 (en) 2001-02-21
IL139018A0 (en) 2001-11-25
WO1999055699A1 (en) 1999-11-04
GB9808894D0 (en) 1998-06-24
AP2000001958A0 (en) 2000-12-31
HUP0102298A2 (en) 2002-05-29
JP2002513020A (en) 2002-05-08
CN1306530A (en) 2001-08-01
KR20010042929A (en) 2001-05-25
BG104973A (en) 2001-09-28
PL343596A1 (en) 2001-08-27
NO20005351D0 (en) 2000-10-24
CA2329913A1 (en) 1999-11-04
SK15902000A3 (en) 2001-05-10
TR200003083T2 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
TR200102021T2 (en) TWEAK and TWEAK receptor antagonists and their use for the treatment of immunological disorders
DE69925571D1 (en) SULPHONAMIDE DERIVATIVES FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
IS6560A (en) Pharmaceutical composition for the treatment of acute, persistent pain and / or nervous system pain and migraine
BR9712783A (en) Anticonvulsant derivatives useful in the treatment of manic-depressive bipolar disorder
ATE224189T1 (en) ANTICONVULSIVE SULFAMATE DERIVATIVES FOR THE TREATMENT OF OBESITY
ES2194960T3 (en) N- (2-SUBSTITUTED-3- (2-AMINOETIL) -1H-INDOL-5-IL) -AMIDAS AS NEW AGONISTS OF 5-HT1F.
DK0751939T5 (en) Naphthylamides as central nervous system agents
ATE253063T1 (en) 5-HT1F AGONISTS
NO20005884L (en) Combination therapy for the treatment of bipolar disorders
BR9809071A (en) Pharmacological agents
PT908458E (en) SUBSTITUTED PYRIDYLMETHYLPIPERAZINE AND PIPERIDINE DERIVATIVES, ITS PREPARATION AND USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES (CNS)
DE60025639D1 (en) SUBSTITUTED DIAZEPAN
BR9609631A (en) 1,6-disubstituted isochromans for the treatment of migraine headaches
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
PT1000046E (en) ACTIVE PIPERAZINE DERIVATIVES IN LOWER URINARY TRACT
DE69735417D1 (en) 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS
EE200000391A (en) Triazine compounds for the treatment of central nervous system disorders
BR0012921A (en) Calcally Compounds
BR0111897A (en) Compound, method for treating an individual afflicted with some disorders of the peripheral and central nervous systems, pharmaceutical composition, and use of a compound
ATE261724T1 (en) ANTICONVULSIVE DERIVATIVES FOR THE TREATMENT OF POST-TRAAUMATIC STRESS DISEASES
DK0935598T3 (en) 5-heteroatom-alkyl-substituted 3-oxopyrido (1,2-a) benzimidazole-4-carboxamide derivatives suitable for the treatment of central nervous system disorders
ATE230741T1 (en) 3-TETRAHYDROPYRIDINE-4-YL-INDOLE FOR THE TREATMENT OF PSYCHOTIC DISORDERS
BR9909878A (en) 10-paroxetine camphosulfonate for treatment of central nervous system disorders
BR0008791A (en) Anticonvulsant derivatives, useful in treating essential tremor

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]